Safety and efficacy of cetuximab combined with chemotherapy in Chinese patients with advanced non-small cell lung cancer.
The aim of this study was to evaluate safety and efficacy of cetuximab combined with chemotherapy in Chinese patients with advanced non-small cell lung cancer (NSCLC). A retrospective analysis of clinical data was conducted in patients who were given cetuximab combined with chemotherapy in the department of respiratory medicine, Peking Union Medical College Hospital between June 2008 and July 2011. All patients signed the informed consent, and consented to offer clinical information. Twenty-two patients were enrolled in this study. Nine patients were alive up to analysis, and the longest survival was 28.9 months. The objective response rate (ORR), disease control rate (DCR), median progression free survival (PFS), and estimated least median overall survival (OS) were 36.4%, 59.1%, 5.3 months and 10.1 months, respectively. Results for the 16 patients treated as first line setting were 50.0%, 62.5%, 6.0 months and 10.1 months, respectively. The common adverse events included skin toxicity (14, 63.6%), alanine aminotransferase elevation (7, 31.8%), hematological toxicity (5, 22.7%), allergy (1, 4.5%) and fever (5, 22.7%). Cetuximab combined with chemotherapy for Chinese patients with advanced NSCLC had promising ORR, DCR, and PFS, especially in the first line subgroup. Serious adverse events had low incidence and were manageable.